HCPro, JustCoding Outpatient - 2021 Issue 8 (February)
Healthcare News: FDA issues EUA for new COVID-19 antibody treatment
February 23rd, 2021
Subscribe or sign in to view the full article.
Article Overview
This news article explains an FDA emergency use authorization for a COVID-19 antibody combination therapy and summarizes the related billing and reimbursement context. It is relevant for clinicians, hospital and outpatient billing staff, coders, and revenue cycle professionals who track COVID-19 treatment authorizations, HCPCS Level II reporting, and Medicare administration payment. The article also notes FDA limitations on use and points readers to an FDA fact sheet for additional guidance.
Why This Topic Matters
The article connects a newly authorized COVID-19 treatment with reporting and payment considerations that affect provider documentation, claims processing, and reimbursement workflows.
What You Will Learn
- What the FDA authorized for COVID-19 treatment
- Which general patient-use limitations are noted in the authorization
- How the article relates the treatment to HCPCS Level II reporting
- What Medicare payment context is described for the therapy
- Where additional FDA guidance is referenced
Who Should Read This
- Medical coders
- Billing specialists
- Revenue cycle staff
- Hospital finance teams
- Clinicians treating COVID-19 patients
Codes Discussed
Subscribe or sign in to view the full article.
Quick, Current, Complete - www.findacode.com